BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Home > article

[Coronavirus] Samsung BioLogics wins deal from Vir Biotechnology to produce candidate material for COVID-19 treatment

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : April 10, 2020, 15:35 | Updated : April 10, 2020, 15:35
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Samsung BioLogics]

SEOUL -- Samsung BioLogics, a leading bio company in South Korea, has clinched a deal worth $360 million to produce candidate materials being developed by Vir Biotechnology, an American clinical-stage immunology company, for the treatment of a novel coronavirus.

Under a binding letter of intent with Samsung BioLogics, Vir Biotechnology, headquartered in San Francisco, will transfer technology this year for the consignment production of candidate materials in 2021. Vir's current development pipeline includes SARS-CoV-2 that causes COVID-19.

The deal with Samsung BioLogics came days after Vir announced a partnership with GlaxoSmithKline plc (GSK), a British healthcare company, to research and develop solutions for coronaviruses, including SARS-CoV-2.

Vir's proprietary monoclonal antibody platform technology will be used to identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the COVID-19 pandemic and future outbreaks. Vir and GSK will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.

Due to the urgent need for COVID-19 solutions, Vir and GSK will focus on the development of specific antibody candidates that have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing the virus in live virus-cellular assays. Subject to regulatory review, they plan to proceed directly into a phase 2 clinical trial within the next three to five months.

Vir and GSK also agreed to conduct research into SARS-CoV-2 and other coronavirus vaccines by coupling GSK's vaccine technologies and expertise with Vir's ability to identify neutralizing epitopes that are present across entire viral families.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .[INTERVIEW] Navers freeware web browser aims to provide open education platform.
    [INTERVIEW] Naver's freeware web browser aims to provide ope…
  • .KT commercializes AI-based non-contact service for postnatal care center.
    KT commercializes AI-based non-contact service for postnatal…
  • .Health officials heave sigh of relief at early introduction of Novavax vaccine .
    Health officials heave sigh of relief at early introduction …
  • .Moon visits announces potential deal with Novavax for 20 mln people: Yonhap.
    Moon visits announces potential deal with Novavax for 20 mln…
  • .Samsung, Kakao and SKT join hands to jointly develop AI to tackle COVID-19 pandemic.
    Samsung, Kakao and SKT join hands to jointly develop AI to t…

Real Time Photo News

  • .Girl band (G)I-DLE shrinks size to five members after school bullying controversy.

    Girl band (G)I-DLE shrinks size to five members after school bullying controversy

  • .Singer-actress IU reveals release schedule for album LILAC.

    Singer-actress IU reveals release schedule for album 'LILAC'

  • .S. Korea to build state-run K-pop concert hall for unaffordable online performances .

    S. Korea to build state-run K-pop concert hall for unaffordable online performances

  • .BLACKPINK member Rosé to release solo album in March.

    BLACKPINK member Rosé to release solo album in March

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

Latest News

more+

  • Girl band (G)I-DLE shrinks size to five members after school bullying controversy
  • S. Korean companies to build combined cycle power plant in Thailand
  • Transparent LED film displays videos and images at official venue of Busan film festival
  • Daredevil surfers to be fined for ignoring storm warning
  • Hanwha Techwin releases CCTVs with fog removal and other functions
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view